Game Changers: Novo Nordisk’s obesity drugs Game Changers: Novo Nordisk’s obesity drugs Game Changers: Novo Nordisk’s obesity drugs

Game Changers: Novo Nordisk’s obesity drugs

Equities 8 minutes to read
Peter Garnry

Head of Saxo Strats

Summary:  In this game changer story we take a look at Novo Nordisk which has grown from being a small pharmaceutical company 30 years to the third most valuable company in Europe driven by constant innovation in insulin drugs and significant increases in productivity and efficiency. Six years ago Novo Nordisk created a new segment called obesity care with the launch of Saxenda. It was the beginning of something big and with the launch of Wegovy seven quarters ago Novo Nordisk's growth has got a new engine that is so hot that investors are thrilled pushing up the stock 122% over the past two years.

The success story of Novo Nordisk

Why write a game changers equity note on an European pharmaceutical company you might be thinking? Why is it even interesting? Novo Nordisk has been one of the winning stocks in Europe over the past 31 years delivering 20.4% annualised return since July 1991 including reinvestment of dividends. The engines behind its success has been its innovation on insulin against diabetes leading to an annualised revenue growth of 10.2% since 1992. During the same period the EBITDA margin has risen from 22.2% to 46.5% as the company has become increasingly more efficient. Its three decade winning streak has taken the company from the lower tiers in the equity market to the third most valuable European company with a market value of €288bn. There are many similarities in the growth journey of Novo Nordisk and the other long-term growth winner ASML from the Netherlands which now the fourth largest company in Europe on market value and considered Europe’s crown jewel. Investor confidence is high in Novo Nordisk seen from high P/E ratio at 30.1 times 2023 expected earnings. The share price is up 122% since March 2021 so most investors would think that it has become too speculative and overvalued. But what if there is a game changer underlying the acceleration in the share price?

A new beginning with saxenda

It all started with the company move into obesity care many years back with its first drug called Saxenda which work by mimicking the natural GLP-1 hormone and thus is effective for suppressing the chemical signals leading to excessive eating. From Q1 2016 to Q1 2021, Saxenda grew from zero revenue to a DKK 5.6bn a year business. Investors were excited as this new obesity care segment had grown to 4.6% of the total business - it looked like Novo Nordisk had found a new significant revenue leg. They had indeed, but it required a new drug. That drug is called Wegovy and is also mimicking the GLP-1 hormone but has a different active compound called samaglutide instead of liraglutide used in Saxenda. Both drugs are on prescription and the patients must have a BMI figure well above the normal range for most humans. Wegovy was FDA approved in early June 2021 and that was the starting point of the big repricing of the stock and the new growth engine.

Wegovy is rocket fuel for Novo Nordisk growth

Since Q2 2021, Wegovy has grown from DKK 100mn business per quarter to DKK 2.4bn per quarter in Q4 2022 and was one of the main drivers behind the revenue and earnings surprise including the FY revenue and operating outlook of 13-19% growth in constant currency. This is a quite high growth rate given the size of Novo Nordisk, but when you look at the numbers you will understand why. Before Wegovy, obesity care was an annual DKK 5.6bn business and now it is DKK 16.9bn in just seven quarters making up 12% of total revenue a big jump from 4% just seven quarters ago. Total revenue in the obesity care segment is up 123% y/y which is the highest growth rate observed for this segment dwarfing even the early days of the Saxenda launch – this alone is quite impressive. According to the Q4 2022 investor presentation, Wegovy is now launched in Denmark and Norway and more countries are expected during 2023.

Are investors getting too optimistic?

Investors might be carried away by the first mover advantage of Novo Nordisk providing an extraordinary opportunity to grab the highest market share for this new category. Novo Nordisk’s biggest competitor is Eli Lilly and the US pharmaceutical company is expected to get FDA approval and launch their own weight loss drug during 2023. The story of Novo Nordisk shows why big gains in equity markets require a catalyst and often a game changing product or business model. Novo Nordisk found a game changer and the future will tell how far it can take Novo Nordisk towards the absolute pinnacle of the global equity market.

Novo Nordisk share price | Source: Saxo


The Saxo Group entities each provide execution-only service, and access to analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Inspiration Disclaimer and (v) Notices applying to Trade Inspiration, Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular, no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Trading in financial instruments carries risk, and may not be suitable for you. Past performance is not indicative of future performance. Please read our disclaimers:
Notification on Non-Independent Investment Research (
Full disclaimer (

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Markets or its affiliates.

Saxo Markets
88 Market Street
CapitaSpring #31-01
Singapore 048948

Contact Saxo

Select region


Saxo Capital Markets Pte Ltd ('Saxo Markets') is a company authorised and regulated by the Monetary Authority of Singapore (MAS) [Co. Reg. No.: 200601141M ] and is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms & Risk Warning to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as Margin FX products may result in your losses exceeding your initial deposits. Saxo Markets does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Markets does not take into account an individual’s needs, objectives or financial situation.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website are not intended for residents of the United States, Malaysia and Japan. Please click here to view our full disclaimer.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.